US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,937.56

+127.434.53%

Number of Gainers:3

Number of Losers:2

Number of Flat:- -

PE:- -

High:3,003.82

Open:2,811.14

Low:2,811.14

Close:2,810.13

Volume:19.70M

Turnover:626.09M

Market Cap:49.01B

Float Cap:45.76B

Loading ...

Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says

MT Newswires Live

Teva Pharmaceutical on Track for Highest Close Since February 2017

Teva's Weltruza Seen as Launch-Execution Story After Clean Label, Oppenheimer Says

MT Newswires Live

Teva Pharmaceutical Industries Says FDA Approved WELTRUZA for Schizophrenia in Adults

MT Newswires Live

Teva announces FDA approval for Weltruza

Dare Bioscience to present Sildenafil Cream data at SMSNA meeting

Daré Bioscience Reports Phase 1 Data Showing 187-Fold Lower Peak Plasma Sildenafil with 3.6% Topical Cream vs Oral Dose

Femasys to Exhibit at ASRM Scientific Congress & Expo

Teva call volume above normal and directionally bullish

Veru Initiated at Buy by WestPark Capital

Veru initiated with a Buy at WestPark Capital

Dare Bioscience - Notified by NASDAQ of Non-Compliance with Minimum Bid Price Requirement - SEC Filing

THOMSON REUTERS

Daré Bioscience Gets NASDAQ Notice After Shares Trade Below $1 Minimum Bid Price

Teva: Additional Analyses Found That Common Concurrent Psychiatric Conditions Did not Negatively Impact Ecopipam's Efficacy or Safety

THOMSON REUTERS

Update: Teva, Samsung Bioepis Partner to Develop, Commercialize Biosimilar Candidates

MT Newswires Live

Teva initiated with a Buy at TD Cowen

Teva, Samsung Bioepis Partner to Develop and Commercialize Biosimilar Candidates

MT Newswires Live

MannKind (MNKD) Jumps On Fresh Momentum As Fair Value Stays In Focus

Simply Wall St.

Press Release: TAPI (Technology & API Services) Names Serge Rogasik CEO to Lead Next Chapter of Growth and Competitiveness

Liquidia ruling has positive read-through for MannKind Tyvaso DPI, says Truist

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hkg.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2937.559,"timestamp":1791575999999,"preClose":2810.1304,"halted":0,"volume":19699950,"delay":0,"changeRate":0.045346,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":127.428711,"latestTime":"10-09 16:00:00 EDT","open":2811.1418,"high":3003.8215,"low":2811.1418,"amount":626086327.101502,"amplitude":0.068566,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.068738,"peRate":74.815861,"turnoverRate":0.013718,"increases":3,"decrements":2,"flats":0,"marketCap":49013269022,"floatMarketCap":45759588707},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":3003.8215,"amplitude":0.068566,"preClose":2810.1304,"low":2811.1418,"pbRate":"6.068738","latestPrice":2937.559,"volume":19699950,"delay":0,"open":2811.1418,"prevYearClose":2379.9924,"prevWeekClose":2838.5862,"prevMonthClose":2843.1685,"prevQuarterClose":2843.1685,"fiveDayClose":2838.5862,"twentyDayClose":2785.0151,"sixtyDayClose":2437.182,"secType":"PLATE","market":"US","turnoverRate":0.013718,"peRate":74.815861,"marketCap":49013269022,"floatMarketCap":45759588707,"timestamp":1791575999999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":3,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674866345","title":"Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2674866345","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674866345?lang=en_us&edition=fundamental","pubTime":"2026-10-10 01:32","pubTimestamp":1791567135,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical (COLL) should benefit from continued strength in its attention-deficit/hyperactivity disorder drugs, limited near-term generic risk for Belbuca and stable pricing trends, whil","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4596","TEVA","COLL","BK4585","BK4584","BK4557","BK4559","BK4588","LU1983299246.USD","ABVC","BK4566","BK4007","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674866558","title":"Teva Pharmaceutical on Track for Highest Close Since February 2017","url":"https://stock-news.laohu8.com/highlight/detail?id=2674866558","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674866558?lang=en_us&edition=fundamental","pubTime":"2026-10-10 01:32","pubTimestamp":1791567120,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries Limited  is currently at $41.55, up $2.30 or 5.86%--Would be highest close since Feb. 15, 2017, when it closed at $51.06--On pace for largest percent increase since Aug. 12, 2026, when it rose 30.28%--Currently up five of the past six days--Currently up three consecutive days; up 6.18% over this period--Best three-day stretch since the three days ending Aug. 14, 2026, when it rose 30.28%--Up 5.11% this week; best weekly performance since the week ending Sept. 18, 2026, when it rose 5.35%--Up 4.92% month-to-date--Up 45.23% year-to-date; on pace for best year since 2024, when it rose 149.59%--Down 39.99% from its all-time closing high of $69.24 on Sept. 1, 2015--Up 107.65% from 52 weeks ago , when it closed at $20.01--Would be a new 52-week closing high--Up 124.59% from its 52-week closing low of $18.50 on Nov. 12, 2025--Traded as high as $42.02; highest intraday level since Feb. 15, 2017, when it hit $51.06--Up 7.06% at today's intraday high; largest intra","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4007","LU2324357040.USD","LU1983299246.USD","BK4566","BK4585","BK4596","TEVA","BK4559","BK4588","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674286523","title":"Teva's Weltruza Seen as Launch-Execution Story After Clean Label, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2674286523","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674286523?lang=en_us&edition=fundamental","pubTime":"2026-10-10 00:52","pubTimestamp":1791564767,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries'  Weltruza approval removes the label risk that defined the long-acting olanzapine debate, leaving launch execution as the key question, Oppenheimer said in a note Friday.With no REMS, no post-injection observation requirement and no boxed warning for post-injection delirium sedation syndrome, Weltruza is the first practical olanzapine LAI, the firm said.Oppenheimer expects a quiet first half of 2027 focused on sampling, hospital formularies and state-by-state Medicaid additions, with meaningful revenue in the second half. It said the launch should be judged on samples, formulary wins and prescriptions, not early sales.The $3,950 monthly list price, 47% above Oppenheimer's initial assumption, signals Teva's confidence in the profile, the firm said. It assumes a 40% gross-to-net discount and flagged rebate depth as the key variable through 2027.Oppenheimer raised its price target to $52 from $50 and reiterated its outperform rating.Price: 41.64, Change: +2","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1983299246.USD","LU2324357040.USD","BK4557","BK4588","BK4566","BK4007","TEVA","BK4559","BK4596","BK4585","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674859554","title":"Teva Pharmaceutical Industries Says FDA Approved WELTRUZA for Schizophrenia in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2674859554","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674859554?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:36","pubTimestamp":1791545799,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  said Friday that the US Food and Drug Administration has approved WELTRUZA for extended-release injectable suspension of olanzapine for subcutaneous use as a treatment of schizophrenia in adults.The company said WELTRUZA will be available in the US in the coming weeks in once-monthly subcutaneous injectable doses of 318 mg, 425 mg and 531 mg.The injections will not require loading doses, oral supplementation, or post-injection monitoring, the company said.Teva said approval was based on results from its phase-3 Solaris trial, which showed a significant reduction in illness severity and improvement in personal and social functioning.The company said the treatment's safety profile was consistent with oral olanzapine, while reported adverse events included weight gain, sleepiness, headache, constipation and injection-site reactions.Shares of the company were up 3.4% in Friday's premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4584","BK4588","LABU","BK4559","BK4596","BK4585","LU1983299246.USD","TEVA","BK4557","BK4007","LU2324357040.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674785642","title":"Teva announces FDA approval for Weltruza","url":"https://stock-news.laohu8.com/highlight/detail?id=2674785642","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674785642?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:05","pubTimestamp":1791543924,"startTime":"0","endTime":"0","summary":"Teva (TEVA) announced that the FDA has approved Weltruza for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","LFSC","TEVA","MRNY","GDOC","BK4588","BK4566","BK4007","IYH","XLVX","BBP","BK4596","IDNA","MEDI","TECB","BMED","LABU","NVIB","BK4557","IBB","LU2324357040.USD","FRTY","BK4584","IEIH","SYNB","GNMX","TBXU","RSPH","LU1983299246.USD","PINK","BK4559","BK4585","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673008528","title":"Dare Bioscience to present Sildenafil Cream data at SMSNA meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2673008528","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673008528?lang=en_us&edition=fundamental","pubTime":"2026-10-08 21:25","pubTimestamp":1791465909,"startTime":"0","endTime":"0","summary":"Dare Bioscience (DARE) announced that clinical data from a Phase 1 study that evaluated the company’s proprietary Sildenafil Cream, 3.6% investigat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dare-bioscience-to-present-sildenafil-cream-data-at-smsna-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dare-bioscience-to-present-sildenafil-cream-data-at-smsna-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","DARE","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673070904","title":"Daré Bioscience Reports Phase 1 Data Showing 187-Fold Lower Peak Plasma Sildenafil with 3.6% Topical Cream vs Oral Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2673070904","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673070904?lang=en_us&edition=fundamental","pubTime":"2026-10-08 21:15","pubTimestamp":1791465319,"startTime":"0","endTime":"0","summary":"Daré Bioscience reports Phase 1 data showing 187-fold lower peak plasma sildenafil with 3.6% topical cream vs oral doseDaré Bioscience disclosed Phase 1 results for a topical sildenafil cream, with da","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL6LNWVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2095319765.USD","IE00BQXX3C00.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4585","IE00BQXX3D17.EUR","BCDF","BK4584","SG9999014039.USD","BK4588","SG9999014005.SGD","BK4112","BK4007","NDAQ","DARE","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673070842","title":"Femasys to Exhibit at ASRM Scientific Congress & Expo","url":"https://stock-news.laohu8.com/highlight/detail?id=2673070842","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673070842?lang=en_us&edition=fundamental","pubTime":"2026-10-08 21:03","pubTimestamp":1791464581,"startTime":"0","endTime":"0","summary":"Femasys to exhibit at ASRM Scientific Congress & ExpoFemasys will exhibit at the ASRM 2026 Scientific Congress & Expo on Oct. 24-28 in Baltimore.Showcase to feature FemaSeed intratubal insemination, a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDLKP7Bp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014039.USD","LU2210149790.SGD","IE00BQXX3D17.EUR","BK4539","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","BK4112","IE00B3QW5Z07.USD","BCDF","IE00B64PRP62.GBP","BK4082","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","IE00BN0W2T93.GBP","BK4588","BK4585","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014005.SGD","FEMY","IE00BQXX3C00.GBP","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673010504","title":"Teva call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2673010504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673010504?lang=en_us&edition=fundamental","pubTime":"2026-10-08 03:45","pubTimestamp":1791402312,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Teva (TEVA) with 7,335 calls trading, 1.2x expected, and implied vol increasing over 2 points to 38.43%. Oct-26 40 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-call-volume-above-normal-and-directionally-bullish-thefly-news-5?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-call-volume-above-normal-and-directionally-bullish-thefly-news-5?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4596","BK4557","LU2324357040.USD","LU1983299246.USD","BK4559","BK4585","BK4584","BK4588","BK4007","TEVA","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673068898","title":"Veru Initiated at Buy by WestPark Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673068898","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673068898?lang=en_us&edition=fundamental","pubTime":"2026-10-07 02:01","pubTimestamp":1791309660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERU/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4007","BK4557","BK4183","VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673706884","title":"Veru initiated with a Buy at WestPark Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673706884","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673706884?lang=en_us&edition=fundamental","pubTime":"2026-10-07 01:40","pubTimestamp":1791308410,"startTime":"0","endTime":"0","summary":"WestPark Capital initiated coverage of Veru (VERU) with a Buy rating and $28 price target Lead asset enbosarm has completed 27 clinical trials acro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veru-initiated-with-a-buy-at-westpark-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veru-initiated-with-a-buy-at-westpark-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4557","DBB","GDOC","BMED","BK4007","IDNA","NVIB","VERU","MEDX","BK4183","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672713746","title":"Dare Bioscience - Notified by NASDAQ of Non-Compliance with Minimum Bid Price Requirement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2672713746","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672713746?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:03","pubTimestamp":1790971400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O0AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4007","DARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672467627","title":"Daré Bioscience Gets NASDAQ Notice After Shares Trade Below $1 Minimum Bid Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2672467627","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672467627?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:02","pubTimestamp":1790971339,"startTime":"0","endTime":"0","summary":"Daré Bioscience gets Nasdaq notice after shares trade below $1 minimum bid priceDaré Bioscience received a Nasdaq notice for failing the $1.00 minimum bid price rule after 30 consecutive business days","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL5xvVQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","BK4584","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672711984","title":"Teva: Additional Analyses Found That Common Concurrent Psychiatric Conditions Did not Negatively Impact Ecopipam's Efficacy or Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2672711984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672711984?lang=en_us&edition=fundamental","pubTime":"2026-10-02 20:00","pubTimestamp":1790942410,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O0SH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4559","BK4588","BK4596","BK4584","LU2324357040.USD","BK4557","BK4585","TEVA","BK4007","BK4566","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672719237","title":"Update: Teva, Samsung Bioepis Partner to Develop, Commercialize Biosimilar Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2672719237","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672719237?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:27","pubTimestamp":1790940462,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  has entered into an agreement with Samsung Bioepis for the global licensing, development, and commercialization of up to six potential biosimilar candidates, the companies said Thursday.Under the deal, South Korea's Samsung Bioepis will manage the development, regulatory registration, and making of the biosimilars. Meanwhile, Teva will be in charge of commercialization in global markets, including the US, Europe, and Canada, with an option to expand to other territories, they said.The companies have confirmed two investigational biosimilar candidates, SB41, referencing Fasenra, and SB44, referencing Ilaris, the companies added.Samsung Bioepis said the parties agreed to keep the total value of the contract confidential, with the deal amount equal to or exceeding the lesser of 2.5% of Samsung Bioepis' 2025 equity or revenue","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4557","BK4585","BK4596","LU1983299246.USD","BK4550","BK4588","BK4566","BK4504","BK4559","BK4584","LU2324357040.USD","EMXC","BK4007","BK4581","TEVA","IEMG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672755497","title":"Teva initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2672755497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672755497?lang=en_us&edition=fundamental","pubTime":"2026-10-01 17:35","pubTimestamp":1790847325,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Joseph Thome initiated coverage of Teva (TEVA) with a Buy rating and $55 price target Teva is a global biopharma company that leve...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","BK4007","BK4588","TEVA","BK4585","BK4566","BK4557","BK4127","BK4584","LU2324357040.USD","BK4559","LU1983299246.USD","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672919755","title":"Teva, Samsung Bioepis Partner to Develop and Commercialize Biosimilar Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2672919755","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672919755?lang=en_us&edition=fundamental","pubTime":"2026-10-01 17:30","pubTimestamp":1790847036,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  has entered into an agreement with Samsung Bioepis for the global licensing, development, and commercialization of up to six potential biosimilar candidates, the companies said on Thursday.Under the deal, South Korea's Samsung Bioepis will manage the development, regulatory registration, and making of the biosimilars. Meanwhile, Teva will be in charge of commercialization in global markets, including the US, Europe, and Canada, with an option to expand to other territories, Teva said.The companies have confirmed two investigational biosimilar candidates, SB41, referencing Fasenra and SB44, referencing Ilaris, it added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4566","BK4588","BK4557","BK4584","EMXC","LU1983299246.USD","BK4559","LU2324357040.USD","BK4550","BK4504","BK4581","IEMG","TEVA","BK4585","BK4007","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672730503","title":"MannKind (MNKD) Jumps On Fresh Momentum As Fair Value Stays In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2672730503","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672730503?lang=en_us&edition=fundamental","pubTime":"2026-10-01 13:12","pubTimestamp":1790831535,"startTime":"0","endTime":"0","summary":"MannKind (MNKD) has drawn fresh attention after a sharp 16.8% one day gain, followed by an 18.5% advance over the past week, raising questions about what this move implies for recent underperformance.\nThat surge comes after a tougher spell for MannKind, with the share price still down 30.4% year to date and the 1-year total shareholder return lower by 29%. The latest bounce hints at improving sentiment rather than a fully repaired long-term track record.\nScan MannKind’s sharp move despite its...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/mannkind-mnkd-jumps-on-fresh-momentum-as-fair-value-stays-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/mannkind-mnkd-jumps-on-fresh-momentum-as-fair-value-stays-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672782213","title":"Press Release: TAPI (Technology & API Services) Names Serge Rogasik CEO to Lead Next Chapter of Growth and Competitiveness","url":"https://stock-news.laohu8.com/highlight/detail?id=2672782213","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672782213?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:32","pubTimestamp":1790800320,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global bu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBB","OTX.SI","BK4588","LU1983299246.USD","BK4559","BK6100","BK4585","BK4566","BK4584","BK4007","LU2324357040.USD","BK6520","BK4557","TEVA","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672789452","title":"Liquidia ruling has positive read-through for MannKind Tyvaso DPI, says Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2672789452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672789452?lang=en_us&edition=fundamental","pubTime":"2026-10-01 01:10","pubTimestamp":1790788218,"startTime":"0","endTime":"0","summary":"Liquidia’s (LQDA) Yutrepia faces a Delaware court finding of infringement of United Therapeutics’ (UTHR) ‘327 patent, pressuring Liquidia shares bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/liquidia-ruling-has-positive-read-through-for-mannkind-tyvaso-dpi-says-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/liquidia-ruling-has-positive-read-through-for-mannkind-tyvaso-dpi-says-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","LQDA","LU1571399168.USD","UTHR","BK4139","LU1699723380.USD","BK4532","USRD","BK4007","MNKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}]}}